Topical Metformin versus Kligman’s Formula for Melasma, a Split-Face JDD Study
This is a must-read article from JDD a head-to-head split-face study asks whether topical metformin can be an effective, gentler option for melasma.
A recent Journal of Drugs in Dermatology article reports a non-randomized, double-blind, split-face comparison assessing topical metformin against Kligman’s triple combination cream in patients with melasma. The 12-week study enrolled 57 adults and used objective melanin index measurements, physician global assessment, Hemi-MASI scoring, and patient satisfaction to determine efficacy while monitoring local tolerability for erythema, burning, and itching.
Both treatments produced measurable reductions in hyperpigmentation by month three, with Kligman’s formula showing a modestly greater effect. Topical metformin also improved pigmentation and was noted as a potential alternative for patients who may be concerned about the adverse effects commonly associated with the triple combination cream. The authors present these findings as preliminary evidence that topical metformin warrants further consideration in clinical practice and larger trials.
For practicing dermatologists and dermatology healthcare professionals this study raises practical questions about integrating novel topical agents into melasma management, weighing efficacy, and tolerability, and interpreting split-face trial data in daily practice. Review the full article to evaluate the methodology, detailed outcome measures, and safety observations that will help inform whether topical metformin could be appropriate for selected patients in your clinic.
Blog write-up assisted by AI
